These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2936 related items for PubMed ID: 25092394

  • 1. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM, Silva MA, Donovan JL, Kanaan AO.
    Clin Ther; 2014 Oct 01; 36(10):1454-64.e3. PubMed ID: 25092394
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, Batson S.
    PLoS One; 2016 Oct 01; 11(8):e0160064. PubMed ID: 27487187
    [Abstract] [Full Text] [Related]

  • 3. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D, Pomero F, Benedetti R, Fenoglio L.
    Intern Emerg Med; 2016 Oct 01; 11(7):895-900. PubMed ID: 27550399
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S.
    PLoS One; 2015 Oct 01; 10(12):e0144856. PubMed ID: 26716830
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH.
    Clin Ther; 2017 Jul 01; 39(7):1456-1478.e36. PubMed ID: 28668628
    [Abstract] [Full Text] [Related]

  • 6. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E.
    Thromb Res; 2014 Oct 01; 134(4):774-82. PubMed ID: 25037495
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT.
    Clin Ther; 2016 Mar 01; 38(3):478-93.e1-16. PubMed ID: 26922297
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.
    Int Angiol; 2014 Aug 01; 33(4):301-8. PubMed ID: 25056161
    [Abstract] [Full Text] [Related]

  • 9. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK, Kirkilesis GI, Tsolakis IA.
    Eur J Vasc Endovasc Surg; 2014 Nov 01; 48(5):565-75. PubMed ID: 24951377
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
    Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV.
    Thromb Res; 2015 May 01; 135(5):888-96. PubMed ID: 25795564
    [Abstract] [Full Text] [Related]

  • 11. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E.
    Vasc Health Risk Manag; 2014 May 01; 10():627-39. PubMed ID: 25404858
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, Billett HH.
    Lancet Haematol; 2019 Jul 01; 6(7):e359-e365. PubMed ID: 31133411
    [Abstract] [Full Text] [Related]

  • 13. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M.
    J Med Econ; 2015 Jun 01; 18(6):399-409. PubMed ID: 25586203
    [Abstract] [Full Text] [Related]

  • 14. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G, Becattini C, Franco L.
    Best Pract Res Clin Haematol; 2013 Jun 01; 26(2):151-61. PubMed ID: 23953903
    [Abstract] [Full Text] [Related]

  • 15. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L, Yeoh SE, Ramli A.
    Cochrane Database Syst Rev; 2017 Dec 15; 12(12):CD011088. PubMed ID: 29244199
    [Abstract] [Full Text] [Related]

  • 16. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul 15; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 17. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A, Gagne JJ, Gopalakrishnan C, Iyer G, Tesfaye H, Brill G, Chin K, Bykov K.
    JAMA; 2022 Mar 15; 327(11):1051-1060. PubMed ID: 35289881
    [Abstract] [Full Text] [Related]

  • 18. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
    Tomkowski W, Kuca P, Bignamini AA, Andreozzi GM.
    Int Angiol; 2017 Oct 15; 36(5):496-497. PubMed ID: 28641408
    [No Abstract] [Full Text] [Related]

  • 19. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV, Hösel V, Ustyugova A, De Francesco M, Lamotte M, Sunderland T.
    J Med Econ; 2016 Oct 15; 19(1):1-10. PubMed ID: 26390231
    [Abstract] [Full Text] [Related]

  • 20. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S.
    Cochrane Database Syst Rev; 2017 Nov 06; 11(11):CD011373. PubMed ID: 29105079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 147.